A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 09 Nov 2018
At a glance
- Drugs Dostarlimab (Primary) ; TSR 033 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms CITRINO
- Sponsors TESARO
- 09 Nov 2018 According to a TESARO media release, preliminary results (n=30) of the monotherapy dose-escalation portion from this study, were presented at the 2018 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Conference in Washington, D.C.
- 09 Nov 2018 Preliminary results (n=30) of the monotherapy dose-escalation portion from this study presented in a TESARO media release.
- 02 Aug 2018 According to a TESARO media release, data from this trial will be presented at the The Society for Immunotherapy of Cancer's (SITC) Annual Meeting